InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,543.22
(
1.61%
)
US TECH 100
19,002.00
(
2.66%
)
Dow Jones
40,563.06
(
1.39%
)
Brent Oil
80.39
(
-0.12%
)
Bitcoin
57,371.61
(
-0.29%
)
Post# of 252897
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120287
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: go seek post# 46647

Monday, 05/14/2007 2:46:57 PM

Monday, May 14, 2007 2:46:57 PM

Post# of 252897
Quiz answer:

>>
1. Generic polysaccharide drugs
2. Generic polypeptide drugs
3. Generic glycoprotein drugs
What is all this in reference to?
<<

This is the progression in MNTA’s business model from easiest to hardest.

Step #1 has already reached the ANDA submission stage for generic Lovenox.

Step #2 is under development with partner NVS to create a generic version of Copaxone. An ANDA will follow.

Step #3 is in early development using two undisclosed glycoproteins designated by NVS. The regulatory path is not yet established.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up